Silmitasertib sodium salt
Based on 60 publication(s) in Google Scholar
Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.91%
- CAS No.: 1309357-15-0
- Formule: C19H11ClN3NaO2
- Masse moléculaire:371.75
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-50855
SilmitasertibCasein Kinase 2 Inhibitor -
HY-14394
TBBCK2 Inhibitor -
HY-15535
DMATCasein Kinase Inhibitor -
HY-15479
TTP 22Casein Kinase Inhibitor -
HY-115519
(E/Z)-GO289CK2 Inhibitor -
HY-10999
TrametinibMEK Inhibitor -
HY-10029
Nutlin-3aMDM2 Antagonist -
HY-10586
5-AzacytidineDNMT Inhibitor -
HY-10182
LaduviglusibGSK-3 Inhibitor -
HY-B0490
Hygromycin BAntibiotic -
HY-12588
Thiamet GO-GlcNAcase Inhibitor -
HY-15593
PinometostatDOT1L Inhibitor
Publications Citing Use of MedChemExpress (MCE) Silmitasertib sodium salt
More- Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]
- Science. 2017 Dec 1;358(6367):eaan4368. [Abstract]
- Cell. 2026 Jun 11;189(12):3541-3552.e18. [Abstract]
- Cell Stem Cell. 2023 Apr 6;30(4):450-459.e9. [Abstract]
- Nat Cell Biol. 2021 Mar;23(3):257-267. [Abstract]
- Autophagy. 2025 Jan;21(1):178-190. [Abstract]
- Nat Commun. 2024 Oct 16;15(1):8912. [Abstract]
- Nat Commun. 2023 Feb 9;14(1):731. [Abstract]
- Metabolism. 2025 Jan:162:156060. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Nat Plants. 2025 Aug;11(8):1572-1590. [Abstract]
- Cell Death Dis. 2024 Mar 16;15(3):223. [Abstract]
- Cell Mol Biol Lett. 2023 Oct 24;28(1):85. [Abstract]
- Cell Death Discov. 2024 Apr 22;10(1):185. [Abstract]
- Oncogene. 2022 Jan;41(4):571-585. [Abstract]
- Oncogene. 2017 Aug 24;36(34):4943-4950. [Abstract]
- Int J Biol Macromol. 2025 Jan:286:138305. [Abstract]
- EMBO Mol Med. 2020 Aug 7;12(8):e11987. [Abstract]
- Cell Rep. 2023 Apr 3;42(4):112339. [Abstract]
- Transl Psychiatry. 2026 Apr 1;16(1):275. [Abstract]
- J Med Chem. 2023 Mar 23;66(6):4009-4024. [Abstract]
- J Med Chem. 2023 Mar 23;66(6):4106-4130. [Abstract]
- Cancer Cell Int. 2024 Dec 26;24(1):432. [Abstract]
- Biochem Pharmacol. 2025 Jul:237:116933. [Abstract]
- Cells. 2021 Jan 18;10(1):181. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Cancer Biol Ther. 2025 Dec;26(1):2457777. [Abstract]
- Int J Mol Sci. 2021 Jan 15;22(2):819. [Abstract]
- Int J Mol Sci. 2020 Mar 3;21(5):1718. [Abstract]
- Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):14. [Abstract]
- PLoS Pathog. 2025 Sep 10;21(9):e1013464. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):20922. [Abstract]
- Cancers (Basel). 2021 Mar 5;13(5):1127. [Abstract]
- Oncol Rep. 2017 Feb;37(2):1141-1147. [Abstract]
- iScience. 2025 Jan 7;28(2):111765. [Abstract]
- Water Biol Secur. 2026 Jul 1.
- J Biol Chem. 2024 Nov;300(11):107848. [Abstract]
- J Immunol. 2023 May 1;210(9):1396-1407. [Abstract]
- Immunol Cell Biol. 2025 Jan;103(1):73-92. [Abstract]
- Vet Microbiol. 2026 Jun 17:320:111115. [Abstract]
- Biochem Biophys Res Commun. 2020 Oct 20;531(3):409-415. [Abstract]
- Drug Res (Stuttg). 2024 Apr;74(4):187-190. [Abstract]
- bioRxiv. 2025 Dec 26:2025.12.24.696284. [Abstract]
- bioRxiv. 2025 Sep 26:2025.09.24.677357. [Abstract]
- University of Washington. 2025.
- Patent. US20250228978A1.
- bioRxiv. 2025 April 09.
- bioRxiv. 2025 February 07.
- bioRxiv. 2024 Nov 6:2024.11.04.621884. [Abstract]
- Biomed Pharmacother. 2024 Sep:178:117191. [Abstract]
- Heliyon. 2024 Aug 18;10(16):e36205. [Abstract]
- bioRxiv. 2024 Jul 25:2024.07.25.605073. [Abstract]
- bioRxiv. 2023 Oct 23:2023.10.20.563266. [Abstract]
- Research Square Preprint. 2023 Oct 27.
- Electronic Theses and Dissertations. 2023 Jul.
- University of Concepcion. 2023.
- Research Square Preprint. 2023 May 26.
- University of California. 2023 Feb.
- Patent. US20180263995A1.
- Oncotarget. 2016 Aug 16;7(33):53191-53203. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Flow Cytometry
-
WB
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Activité biologique
Description
IC50 & Target
[1]|
CK2α 1 nM (IC50) |
CK2α' 1 nM (IC50) |
In Vitro
Silmitasertib (CX-4945) causes cell-cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells, attenuates PI3K/Akt signalingand, and the antiproliferative activity of Silmitasertib (CX-4945) is correlated with expression levels of the CK2α catalytic subunit, Attenuation of PI3K/Akt signaling[1]. Silmitasertib (CX-4945) with PS-341 treatment prevents leukemic cells from engaging a functional UPR in order to buffer the PS-341-mediated proteotoxic stress in ER lumen, and decreases pro-survival ER chaperon BIP/Grp78 expression[2]. Silmitasertib (CX-4945) induces cytotoxicity and apoptosis, and exerts anti-proliferative effects in hematological tumors by downregulating CK2 expression and suppressing activation of CK2-mediated PI3K/Akt/mTOR signaling pathways[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1309357-15-0
-
Appearance Solid
-
Masse moléculaire 371.75
-
Formule C19H11ClN3NaO2
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC=C2C3=C(C(NC4=CC=CC(Cl)=C4)=NC2=C1)C=CN=C3)O[Na]
-
Synonyms
CX-4945 sodium salt
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (60)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2023 May 10;8(1):183. PMID: 37160887 -
Science
2017 Dec 1;358(6367):eaan4368. PMID: 29191878 -
Cell
2026 Jun 11;189(12):3541-3552.e18. PMID: 41999746 -
Cell Stem Cell
Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming. [Abstract]2023 Apr 6;30(4):450-459.e9. PMID: 36944335 -
Nat Cell Biol
TGF-β-induced DACT1 biomolecular condensates repress Wnt signalling to promote bone metastasis. [Abstract]2021 Mar;23(3):257-267. PMID: 33723425
Silmitasertib sodium salt purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2021 Mar;23(3):257-267. [Abstract]
BM2-TGC cells expressing either vector or DACT1 were treated with Wnt3a +/− Silmitasertib at 5 μM for 24h.
-
Autophagy
TRIM21-mediated ubiquitination of SQSTM1/p62 abolishes its Ser403 phosphorylation and enhances palmitic acid cytotoxicity. [Abstract]2025 Jan;21(1):178-190. PMID: 39172027 -
Nat Commun
Phosphorylation-driven epichaperome assembly is a regulator of cellular adaptability and proliferation. [Abstract]2024 Oct 16;15(1):8912. PMID: 39414766 -
Nat Commun
Angiotensin-converting enzyme inhibitor promotes angiogenesis through Sp1/Sp3-mediated inhibition of notch signaling in male mice. [Abstract]2023 Feb 9;14(1):731. PMID: 36759621 -
Metabolism
Body weight control via protein kinase CK2: diet-induced obesity counteracted by pharmacological targeting. [Abstract]2025 Jan:162:156060. PMID: 39521118 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Nat Plants
CK2 kinase-PRC2 signalling regulates genome-wide H3K27 trimethylation and transduces prolonged cold exposure into epigenetic cold memory in plants. [Abstract]2025 Aug;11(8):1572-1590. PMID: 40750695 -
Cell Death Dis
Casein kinase 2 phosphorylates and induces the SALL2 tumor suppressor degradation in colon cancer cells. [Abstract]2024 Mar 16;15(3):223. PMID: 38493149 -
Cell Mol Biol Lett
Inhibition of SQSTM1 S403 phosphorylation facilitates the aggresome formation of ubiquitinated proteins during proteasome dysfunction. [Abstract]2023 Oct 24;28(1):85. PMID: 37872526 -
Cell Death Discov
CK2α-mediated phosphorylation of GRP94 facilitates the metastatic cascade in triple-negative breast cancer. [Abstract]2024 Apr 22;10(1):185. PMID: 38649679
Silmitasertib sodium salt purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Apr 22;10(1):185. [Abstract]
CK2α kinase activity was measured after treatment with silmitasertib (20 μM, 24 h). Cell lysates were used for in vitro kinase assay to detect the intensity of phosphorylated substrate.
-
Oncogene
Histone N-terminal acetyltransferase NAA40 links one-carbon metabolism to chemoresistance. [Abstract]2022 Jan;41(4):571-585. PMID: 34785778 -
Oncogene
2017 Aug 24;36(34):4943-4950. PMID: 28436950 -
Int J Biol Macromol
Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation. [Abstract]2025 Jan:286:138305. PMID: 39631575 -
EMBO Mol Med
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer. [Abstract]2020 Aug 7;12(8):e11987. PMID: 32672423 -
Cell Rep
2023 Apr 3;42(4):112339. PMID: 37014752 -
Transl Psychiatry
Non-gene-edited neural stem cells reverse neuroinflammation and microbiota dysbiosis in a sprague-dawley rat model of autism spectrum disorder. [Abstract]2026 Apr 1;16(1):275. PMID: 41922322 -
J Med Chem
Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective. [Abstract]2023 Mar 23;66(6):4009-4024. PMID: 36883902 -
J Med Chem
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. [Abstract]2023 Mar 23;66(6):4106-4130. PMID: 36876904 -
Cancer Cell Int
Protein kinase CK2 sustains de novo fatty acid synthesis by regulating the expression of SCD-1 in human renal cancer cells. [Abstract]2024 Dec 26;24(1):432. PMID: 39726006 -
Biochem Pharmacol
The dual targeting effects of KD025 on casein kinase 2 and ROCK2 in a mouse model of diet-induced obesity. [Abstract]2025 Jul:237:116933. PMID: 40210126 -
Cells
Contribution of the CK2 Catalytic Isoforms α and α' to the Glycolytic Phenotype of Tumor Cells. [Abstract]2021 Jan 18;10(1):181. PMID: 33477590
Silmitasertib sodium salt purchased from MedChemExpress. Usage Cited in: Cells. 2021 Jan 18;10(1):181. [Abstract]
w.t. SK-N-BE cells were treated with CX-4945 (5-10 μM, 24-48 h) at the indicated time and concentration conditions. 30 μg proteins from lysates were analyzed by WB for the HIF-1α levels. Actin was used as loading control.
Silmitasertib sodium salt purchased from MedChemExpress. Usage Cited in: Cells. 2021 Jan 18;10(1):181. [Abstract]
SK-N-BE and U2OS cells were analyzed for the extracellular lactate secreted in the culture medium in 6 h, in the absence or in the presence of the indicated concentrations of CX-4945 (5-15 μM).
Silmitasertib sodium salt purchased from MedChemExpress. Usage Cited in: Cells. 2021 Jan 18;10(1):181. [Abstract]
SK-N-BE cells glycolytic stress test profile, upon treatment with vehicle (control) or the indicated concentration of CX-4945 (2-5 ，μM) for 5 h before running the Seahorse experiment.
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Cancer Biol Ther
Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia. [Abstract]2025 Dec;26(1):2457777. PMID: 39862423 -
Int J Mol Sci
Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2. [Abstract]2021 Jan 15;22(2):819. PMID: 33467550 -
Int J Mol Sci
2020 Mar 3;21(5):1718. PMID: 32138279 -
Invest Ophthalmol Vis Sci
Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma. [Abstract]2022 Dec 1;63(13):14. PMID: 36515935 -
PLoS Pathog
CK2 derived from brain microvascular endothelial cells induces astrocyte inflammatory response in Escherichia coli-induced meningitis. [Abstract]2025 Sep 10;21(9):e1013464. PMID: 40929057 -
Sci Rep
Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with chemotherapeutic agents in cisplatin resistant bladder cancer cells. [Abstract]2025 Jul 1;15(1):20922. PMID: 40594996 -
Cancers (Basel)
Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. [Abstract]2021 Mar 5;13(5):1127. PMID: 33807974 -
Oncol Rep
2017 Feb;37(2):1141-1147. PMID: 27959425
Silmitasertib sodium salt purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2017 Feb;37(2):1141-1147. [Abstract]
CX-4945 increases the expression of apoptosis markers. Western blot analysis reveals that CX-4945 treatment increases the expression of cleaved PARP or cleaved caspase-3. CX-4945 treatment decreases the expression of Bcl-2 or Bcl-xL. The experiment is performed in triplicate, producing similar results.
-
iScience
Single-cell and spatial transcriptomics reveal pre-metastatic subsets and therapeutic targets in penile carcinoma. [Abstract]2025 Jan 7;28(2):111765. PMID: 39925432 -
-
J Biol Chem
Nerve injury augments Cacna2d1 transcription via CK2-mediated phosphorylation of the histone deacetylase HDAC2 in dorsal root ganglia. [Abstract]2024 Nov;300(11):107848. PMID: 39357831 -
J Immunol
Dephosphorylation of T517 on Hemocyanin Is Required for Antibacterial Activity in Penaeus vannamei. [Abstract]2023 May 1;210(9):1396-1407. PMID: 36971684 -
Immunol Cell Biol
RNAi library screening reveals Gβ1, Casein Kinase 2 and ICAP-1 as novel regulators of LFA-1-mediated T cell polarity and migration. [Abstract]2025 Jan;103(1):73-92. PMID: 39607284 -
Vet Microbiol
Pseudorabies virus EP0 recruits TECPR2 and CK2 to promote COPII accumulation and viral egress. [Abstract]2026 Jun 17:320:111115. PMID: 42322707 -
Biochem Biophys Res Commun
A N-terminally deleted form of the CK2α' catalytic subunit is sufficient to support cell viability. [Abstract]2020 Oct 20;531(3):409-415. PMID: 32800562 -
Drug Res (Stuttg)
Preclinical Targeting of the PGRMC1-CK2 Axis with Silmitasertib: A Potential Strategy for Lung Adenocarcinoma Therapy. [Abstract]2024 Apr;74(4):187-190. PMID: 38508228 -
bioRxiv
CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteins. [Abstract]2025 Dec 26:2025.12.24.696284. PMID: 41509496 -
bioRxiv
CK2 inhibitor CX-4945 targets EWS-FLI1 protein abundance and shows anti-tumor activity in metastatic mouse models of Ewing Sarcoma. [Abstract]2025 Sep 26:2025.09.24.677357. PMID: 41040216 -
-
-
-
-
bioRxiv
PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]2024 Nov 6:2024.11.04.621884. PMID: 39574568 -
Biomed Pharmacother
Pharmacological inhibition of CK2 by silmitasertib mitigates sepsis-induced circulatory collapse, thus improving septic outcomes in mice. [Abstract]2024 Sep:178:117191. PMID: 39079263 -
Heliyon
Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target. [Abstract]2024 Aug 18;10(16):e36205. PMID: 39253198 -
bioRxiv
Spindle morphology changes between meiosis and mitosis driven by CK2 regulation of the Ran pathway. [Abstract]2024 Jul 25:2024.07.25.605073. PMID: 39211121 -
bioRxiv
Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbations. [Abstract]2023 Oct 23:2023.10.20.563266. PMID: 37961516 -
-
-
-
-
-
-
Oncotarget
2016 Aug 16;7(33):53191-53203. PMID: 27448963
Silmitasertib sodium salt purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Aug 16;7(33):53191-53203. [Abstract]
MPNST cell lines show a decrease in CK2 activity in response to escalating CX-4945 concentrations (24 h) as measured by a western blot analysis using anti-CK2 substrate, and to undergo apoptosis as indicated by increased cleaved PARP.
Solvant et solubilité
In Vitro:
DMSO : 87.5 mg/mL (235.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 16.67 mg/mL (44.84 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (67.25 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocole
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98. [Content Brief]
[2]. Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203. [Content Brief]
[3]. Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40. [Content Brief]
[4]. Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.6900 mL | 13.4499 mL | 26.8998 mL | 67.2495 mL |
| 5 mM | 0.5380 mL | 2.6900 mL | 5.3800 mL | 13.4499 mL | |
| 10 mM | 0.2690 mL | 1.3450 mL | 2.6900 mL | 6.7249 mL | |
| 15 mM | 0.1793 mL | 0.8967 mL | 1.7933 mL | 4.4833 mL | |
| 20 mM | 0.1345 mL | 0.6725 mL | 1.3450 mL | 3.3625 mL | |
| 25 mM | 0.1076 mL | 0.5380 mL | 1.0760 mL | 2.6900 mL | |
| 30 mM | 0.0897 mL | 0.4483 mL | 0.8967 mL | 2.2416 mL | |
| 40 mM | 0.0672 mL | 0.3362 mL | 0.6725 mL | 1.6812 mL | |
| DMSO | 50 mM | 0.0538 mL | 0.2690 mL | 0.5380 mL | 1.3450 mL |
| 60 mM | 0.0448 mL | 0.2242 mL | 0.4483 mL | 1.1208 mL | |
| 80 mM | 0.0336 mL | 0.1681 mL | 0.3362 mL | 0.8406 mL | |
| 100 mM | 0.0269 mL | 0.1345 mL | 0.2690 mL | 0.6725 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Silmitasertib sodium salt Related Classifications
HY-50855B Related Classifications
Powered by Bioz